Antibodies News and Research

RSS

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

Researchers at the Eberhard Karls University and the University of Tübingen in Germany described 11 unique nanobodies (Nbs) specific for the SARS-CoV-2 spike receptor-binding domain (RBD), of which 8 Nbs potentially inhibit the connection of RBD with the angiotensin-converting enzyme 2 (ACE2).

3 May 2021

Study reveals new broadly neutralizing and protective antibody against coronaviruses

In the setting of potentially reduced vaccine efficacy against coronavirus disease (COVID-19) due to emerging viral variants, the deployment of effective treatments based on monoclonal antibodies may be an additional strategy to help control the pandemic. A new study by US researchers, currently available on the bioRxiv* preprint server, describes the action of a specific antibody known as DH1047.

3 May 2021

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

A study recently published in the journal Matter has demonstrated the development and validation of a nanoparticle-based formulation, capable of completely inhibiting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection blocking the interaction between viral spike protein and host cell angiotensin-converting enzyme 2 (ACE2).

3 May 2021

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants of concern

Researchers in the United States have conducted a study demonstrating the effectiveness of first-generation vaccines at protecting against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals who have previously been infected with the virus.

2 May 2021

Single dose of vaccine boosts protection only in people previously infected by COVID-19

A single dose of vaccine boosts protection against SARS-CoV-2 coronavirus variants, but only in those with previous COVID-19, a study has found.

30 Apr 2021

Applications of nanoparticles in combating COVID-19

Researchers review the various properties and use of nanoparticles in targeting SARS-CoV-2 and how they could be used to develop new therapeutics and diagnostics for SARS-CoV-2.

30 Apr 2021

Hepatitis C antivirals synergize with remdesivir to inhibit SARS-CoV-2 in vitro

A new study sheds light on the potential of drug combinations to stem viral transmission and treat patients with COVID-19. It also shows that four drugs used to treat hepatitis C synergize with remdesivir to make it up to ten times more effective at inhibiting SARS-CoV-2 in cell cultures.

30 Apr 2021

Could COVID-19 rapid antigen tests aid international border control measures?

A recent study has explored the use of rapid antigen testing for COVID-19 at borders to reduce community transmission, and concluded that it would be effective only at lower volumes of passenger traffic.

30 Apr 2021

Human to animal transmission of SARS-CoV-2 in households is common

Coronaviruses are seen in multiple mammalian species. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, is said to have passed to humans from a mammalian source and to have originated from an animal reservoir as a zoonotic pathogen.

29 Apr 2021

Guidance on diagnosis and management of cerebral venous sinus thrombosis after a COVID-19 vaccine

Last Friday, the Centers for Disease Control and Prevention and the U.S. Food & Drug Administration lifted the pause in administration of the Johnson & Johnson (Janssen) COVID-19 vaccine in the U.S.

29 Apr 2021

Researchers characterize a large set of therapeutic antibodies against SARS-CoV-2 variants

A team of scientists from A-Alpha Bio., USA, has recently conducted a large-scale screening of 33 therapeutic antibodies to examine their binding affinity to a number of SARS-CoV-2 variants. The team analyzed the impact of potential mutations in the spike RBD on antibody efficacy.

29 Apr 2021

City of Hope initiates Phase 2 clinical trial to investigate if mushroom tablets could slow prostate cancer

City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, is now recruiting patients for a Phase 2 clinical trial to investigate whether pills containing white button mushroom extract could regulate the immune system, affecting prostate-specific antigen (PSA) levels to either remain stable or decline.

29 Apr 2021

Repairing faulty drains could be key to unlocking the potential of Alzheimer's therapies

Experimental Alzheimer's drugs have shown little success in slowing declines in memory and thinking, leaving scientists searching for explanations.

29 Apr 2021

New insights into how South African SARS-CoV-2 variant sacrifices tight binding for antibody evasion

The highly infectious SARS-CoV-2 variant that recently emerged in South Africa, known as B.1.351, has scientists wondering how existing COVID-19 vaccines and therapies can be improved to ensure strong protection.

29 Apr 2021

Potent monoclonal antibody shows promise against emerging SARS-CoV-2 variants of concern

In a new study currently available on the bioRxiv* preprint server, a group of US-based researchers developed a panel of neutralizing monoclonal antibodies against SARS-CoV-2 that can block viral attachment to cells – and pinpointed a specific one that can potently neutralize all tested variants of concern.

28 Apr 2021

Recovered COVID-19 patients show signs of long-term immunity

A study conducted by researchers in the United States has found that most patients who recovered from coronavirus disease 2019 (COVID-19) showed signs of long-lasting immunity against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Apr 2021

Nanobodies may be the key to blocking tick-borne bacterial infection

Tiny molecules called nanobodies, which can be designed to mimic antibody structures and functions, may be the key to blocking a tick-borne bacterial infection that remains out of reach of almost all antibiotics, new research suggests.

28 Apr 2021

Study examines mRNA COVID-19 vaccine’s effectiveness across age and gender

The findings reveal that although the two-dose vaccine regimen initially induces robust antibody response in all age groups, older male individuals are particularly associated with a gradual decline in vaccine-induced immunity six weeks after the second vaccine dose.

28 Apr 2021

COVID-19 donor antibodies show broad cross-reactivity against SARS-CoV-2 variants and related viruses

A new study reports on a set of antibodies from COVID-19 donor serum, which seems to be cross-reactive across multiple Sarbecoviruses, including the very similar SARS-CoV-2, SARS-CoV and Middle East Respiratory Syndrome (MERS)-CoV.

28 Apr 2021

You don’t have to suffer to benefit from Covid vaccination — but some prefer it

If you think vaccination is an ordeal now, consider the 18th-century version. After having pus from a smallpox boil scratched into your arm, you would be subject to three weeks of fever, sweats, chills, bleeding and purging with dangerous medicines, accompanied by hymns, prayers and hell-fire sermons by dour preachers.

28 Apr 2021

Antibodies News and Research

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

Study reveals new broadly neutralizing and protective antibody against coronaviruses

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants of concern

Single dose of vaccine boosts protection only in people previously infected by COVID-19

Applications of nanoparticles in combating COVID-19

Hepatitis C antivirals synergize with remdesivir to inhibit SARS-CoV-2 in vitro

Could COVID-19 rapid antigen tests aid international border control measures?

Human to animal transmission of SARS-CoV-2 in households is common

Guidance on diagnosis and management of cerebral venous sinus thrombosis after a COVID-19 vaccine

Researchers characterize a large set of therapeutic antibodies against SARS-CoV-2 variants

City of Hope initiates Phase 2 clinical trial to investigate if mushroom tablets could slow prostate cancer

Repairing faulty drains could be key to unlocking the potential of Alzheimer's therapies

New insights into how South African SARS-CoV-2 variant sacrifices tight binding for antibody evasion

Potent monoclonal antibody shows promise against emerging SARS-CoV-2 variants of concern

Recovered COVID-19 patients show signs of long-term immunity

Nanobodies may be the key to blocking tick-borne bacterial infection

Study examines mRNA COVID-19 vaccine’s effectiveness across age and gender

COVID-19 donor antibodies show broad cross-reactivity against SARS-CoV-2 variants and related viruses

You don’t have to suffer to benefit from Covid vaccination — but some prefer it

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo